THNR Amplify Weight Loss Drug & Treatment ETF
The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.
No price history on file.
Performance
| 1M | 3M | YTD | 1Y | 3Y ann. | 5Y ann. | |
|---|---|---|---|---|---|---|
| THNR | — | — | — | — | — | — |
| Equity average (4726 funds) | -2.6% | -5.1% | +7169.5% | +4568.0% | +16.3% | +3.4% |
Insider activity in the holdings
Open-market insider buying across this fund’s holdings over 90 days, weighted by holding weight: +$0 net.
No open-market insider buys in the holdings in the last 90 days.
Holdings · as of Nov 13, 2026
| # | Holding | Weight |
|---|---|---|
| 1 | LLY Eli Lilly & Co | 11.98% |
| 2 | NVO Novo Nordisk A/S | 8.71% |
| 3 | AMGN Amgen Inc | 6.14% |
| 4 | REGN Regeneron Pharmaceuticals Inc | 6.04% |
| 5 | AZN AstraZeneca PLC | 5.81% |
| 6 | ROP.SW Roche Holding AG | 5.74% |
| 7 | GILD Gilead Sciences Inc | 5.67% |
| 8 | ABBV AbbVie Inc | 5.65% |
| 9 | PFE Pfizer Inc | 5.24% |
| 10 | 4519.T Chugai Pharmaceutical Co Ltd | 5.16% |
| 11 | MRK Merck & Co Inc | 4.97% |
| 12 | 1093.HK CSPC Pharmaceutical Group Ltd | 4.65% |
| 13 | 1801.HK Innovent Biologics Inc | 4.48% |
| 14 | VKTX Viking Therapeutics Inc | 4.20% |
| 15 | ZEAL.CO Zealand Pharma A/S | 3.30% |
| 16 | 128940.KS Hanmi Pharm Co Ltd | 3.26% |
| 17 | ARWR Arrowhead Pharmaceuticals Inc | 2.78% |
| 18 | 1276.HK Jiangsu Hengrui Pharmaceuticals Co Ltd | 2.30% |
| 19 | GPCR Structure Therapeutics Inc | 2.02% |
| 20 | KLRA Kailera Therapeutics Inc | 1.10% |
| 21 | AGPXX Invesco Government & Agency Portfolio 12/31/2031 | 0.48% |
| 22 | THNR Cash & Other | 0.33% |
Sector breakdown
Not on file.
Country breakdown
Not on file.
Distributions
No distributions on file.
Members of Congress who disclosed this ETF
No member of Congress has disclosed a trade in THNR in the filings we hold.
Fund facts, prices, performance and distributions: our market-data vendor. Holdings: the vendor and SEC Form N-PORT. Insider and Congress data: InsiderBuying. Last updated Nov 19, 2026. This is historical data, not investment advice. Report a data error
